The diagnostic and prognostic value of the miR-17-92 cluster in hepatocellular carcinoma: A meta-analysis
Previous studies demonstrated that microRNAs (miRNAs) could serve as biomarkers in various cancers. This meta-analysis aimed to determine the roles of a miR-17-92 cluster in hepatocellular carcinoma (HCC). Here, eligible included studies were searched through PubMed, Embase, and Wan Fang databases u...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-09-01
|
| Series: | Frontiers in Genetics |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fgene.2022.927079/full |
| _version_ | 1798025780245037056 |
|---|---|
| author | Fang Lu Fang Lu Xianghong Zhao Xianghong Zhao Zhongqiu Zhang Zhongqiu Zhang Mengqiu Xiong Ying Wang Ying Wang Yalan Sun Yalan Sun Bangshun He Bangshun He Junrong Zhu Junrong Zhu |
| author_facet | Fang Lu Fang Lu Xianghong Zhao Xianghong Zhao Zhongqiu Zhang Zhongqiu Zhang Mengqiu Xiong Ying Wang Ying Wang Yalan Sun Yalan Sun Bangshun He Bangshun He Junrong Zhu Junrong Zhu |
| author_sort | Fang Lu |
| collection | DOAJ |
| description | Previous studies demonstrated that microRNAs (miRNAs) could serve as biomarkers in various cancers. This meta-analysis aimed to determine the roles of a miR-17-92 cluster in hepatocellular carcinoma (HCC). Here, eligible included studies were searched through PubMed, Embase, and Wan Fang databases up to 1st February 2022. Relevant data were extracted from each eligible study to evaluate the relationship between miRNA-17-92 cluster miRNA expression and the diagnosis and prognosis of HCC. Finally, a total of 21 studies were pooled and included in the meta-analysis, of which four articles were used for diagnostic meta-analysis and eight articles were used for prognostic meta-analysis. The pooled sensitivity, specificity, and diagnostic odds ratios (DOR) of the miR17-92 cluster for diagnosis of HCC were 0.75 [95% confidence interval (CI): 0.64–0.83], 0.73 (95% CI: 0.65–0.79), and 7.87 (95% CI: 5.36–11.54), respectively. Also, the area under the curve (AUC) for the miR-17-92 cluster when diagnosing HCC was 0.79 (95% CI: 0.76–0.83). For prognostic analysis, hazard ratios (HRs) with 95% CIs were extracted from the included studies and pooled HRs were determined to assess the associations. Patients with increased expression of miR17-92 cluster miRNA were associated with poor overall survival (OS) and recurrence-free survival (RFS) (HR=1.86, 95% CI: 1.04–3.33; HR = 4.18, 95% CI: 3.02–5.77, respectively), but not progression-free survival (PFS) (HR = 0.43, 95% CI: 0.25–0.73), while no association of the miR-17-92 cluster high-expression was detected with disease-free survival (DFS) (HR: 0.95, 95% CI: 0.21–4.34). In short, current pieces of evidence suggested that the miR-17-92 cluster may serve as a novel diagnostic and prognostic biomarker for HCC. However, given the limited study number, larger-size, multi-center, and higher-quality studies are indispensable in the future. |
| first_indexed | 2024-04-11T18:24:20Z |
| format | Article |
| id | doaj.art-92dbcfd60c2346e3afb9d280fbd2b8d2 |
| institution | Directory Open Access Journal |
| issn | 1664-8021 |
| language | English |
| last_indexed | 2024-04-11T18:24:20Z |
| publishDate | 2022-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Genetics |
| spelling | doaj.art-92dbcfd60c2346e3afb9d280fbd2b8d22022-12-22T04:09:41ZengFrontiers Media S.A.Frontiers in Genetics1664-80212022-09-011310.3389/fgene.2022.927079927079The diagnostic and prognostic value of the miR-17-92 cluster in hepatocellular carcinoma: A meta-analysisFang Lu0Fang Lu1Xianghong Zhao2Xianghong Zhao3Zhongqiu Zhang4Zhongqiu Zhang5Mengqiu Xiong6Ying Wang7Ying Wang8Yalan Sun9Yalan Sun10Bangshun He11Bangshun He12Junrong Zhu13Junrong Zhu14School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, ChinaDepartment of Pharmacy, Nanjing First Hospital, China Pharmaceutical University, Nanjing, ChinaSchool of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, ChinaDepartment of Pharmacy, Nanjing First Hospital, China Pharmaceutical University, Nanjing, ChinaSchool of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, ChinaDepartment of Pharmacy, Nanjing First Hospital, China Pharmaceutical University, Nanjing, ChinaDepartment of Laboratory Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, ChinaSchool of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, ChinaDepartment of Pharmacy, Nanjing First Hospital, China Pharmaceutical University, Nanjing, ChinaSchool of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, ChinaDepartment of Pharmacy, Nanjing First Hospital, China Pharmaceutical University, Nanjing, ChinaSchool of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, ChinaDepartment of Laboratory Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, ChinaSchool of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, ChinaDepartment of Pharmacy, Nanjing First Hospital, China Pharmaceutical University, Nanjing, ChinaPrevious studies demonstrated that microRNAs (miRNAs) could serve as biomarkers in various cancers. This meta-analysis aimed to determine the roles of a miR-17-92 cluster in hepatocellular carcinoma (HCC). Here, eligible included studies were searched through PubMed, Embase, and Wan Fang databases up to 1st February 2022. Relevant data were extracted from each eligible study to evaluate the relationship between miRNA-17-92 cluster miRNA expression and the diagnosis and prognosis of HCC. Finally, a total of 21 studies were pooled and included in the meta-analysis, of which four articles were used for diagnostic meta-analysis and eight articles were used for prognostic meta-analysis. The pooled sensitivity, specificity, and diagnostic odds ratios (DOR) of the miR17-92 cluster for diagnosis of HCC were 0.75 [95% confidence interval (CI): 0.64–0.83], 0.73 (95% CI: 0.65–0.79), and 7.87 (95% CI: 5.36–11.54), respectively. Also, the area under the curve (AUC) for the miR-17-92 cluster when diagnosing HCC was 0.79 (95% CI: 0.76–0.83). For prognostic analysis, hazard ratios (HRs) with 95% CIs were extracted from the included studies and pooled HRs were determined to assess the associations. Patients with increased expression of miR17-92 cluster miRNA were associated with poor overall survival (OS) and recurrence-free survival (RFS) (HR=1.86, 95% CI: 1.04–3.33; HR = 4.18, 95% CI: 3.02–5.77, respectively), but not progression-free survival (PFS) (HR = 0.43, 95% CI: 0.25–0.73), while no association of the miR-17-92 cluster high-expression was detected with disease-free survival (DFS) (HR: 0.95, 95% CI: 0.21–4.34). In short, current pieces of evidence suggested that the miR-17-92 cluster may serve as a novel diagnostic and prognostic biomarker for HCC. However, given the limited study number, larger-size, multi-center, and higher-quality studies are indispensable in the future.https://www.frontiersin.org/articles/10.3389/fgene.2022.927079/fullmiR-17-92 clusterhepatocellular carcinomadiagnostic valueprognostic valuemeta-analysis |
| spellingShingle | Fang Lu Fang Lu Xianghong Zhao Xianghong Zhao Zhongqiu Zhang Zhongqiu Zhang Mengqiu Xiong Ying Wang Ying Wang Yalan Sun Yalan Sun Bangshun He Bangshun He Junrong Zhu Junrong Zhu The diagnostic and prognostic value of the miR-17-92 cluster in hepatocellular carcinoma: A meta-analysis Frontiers in Genetics miR-17-92 cluster hepatocellular carcinoma diagnostic value prognostic value meta-analysis |
| title | The diagnostic and prognostic value of the miR-17-92 cluster in hepatocellular carcinoma: A meta-analysis |
| title_full | The diagnostic and prognostic value of the miR-17-92 cluster in hepatocellular carcinoma: A meta-analysis |
| title_fullStr | The diagnostic and prognostic value of the miR-17-92 cluster in hepatocellular carcinoma: A meta-analysis |
| title_full_unstemmed | The diagnostic and prognostic value of the miR-17-92 cluster in hepatocellular carcinoma: A meta-analysis |
| title_short | The diagnostic and prognostic value of the miR-17-92 cluster in hepatocellular carcinoma: A meta-analysis |
| title_sort | diagnostic and prognostic value of the mir 17 92 cluster in hepatocellular carcinoma a meta analysis |
| topic | miR-17-92 cluster hepatocellular carcinoma diagnostic value prognostic value meta-analysis |
| url | https://www.frontiersin.org/articles/10.3389/fgene.2022.927079/full |
| work_keys_str_mv | AT fanglu thediagnosticandprognosticvalueofthemir1792clusterinhepatocellularcarcinomaametaanalysis AT fanglu thediagnosticandprognosticvalueofthemir1792clusterinhepatocellularcarcinomaametaanalysis AT xianghongzhao thediagnosticandprognosticvalueofthemir1792clusterinhepatocellularcarcinomaametaanalysis AT xianghongzhao thediagnosticandprognosticvalueofthemir1792clusterinhepatocellularcarcinomaametaanalysis AT zhongqiuzhang thediagnosticandprognosticvalueofthemir1792clusterinhepatocellularcarcinomaametaanalysis AT zhongqiuzhang thediagnosticandprognosticvalueofthemir1792clusterinhepatocellularcarcinomaametaanalysis AT mengqiuxiong thediagnosticandprognosticvalueofthemir1792clusterinhepatocellularcarcinomaametaanalysis AT yingwang thediagnosticandprognosticvalueofthemir1792clusterinhepatocellularcarcinomaametaanalysis AT yingwang thediagnosticandprognosticvalueofthemir1792clusterinhepatocellularcarcinomaametaanalysis AT yalansun thediagnosticandprognosticvalueofthemir1792clusterinhepatocellularcarcinomaametaanalysis AT yalansun thediagnosticandprognosticvalueofthemir1792clusterinhepatocellularcarcinomaametaanalysis AT bangshunhe thediagnosticandprognosticvalueofthemir1792clusterinhepatocellularcarcinomaametaanalysis AT bangshunhe thediagnosticandprognosticvalueofthemir1792clusterinhepatocellularcarcinomaametaanalysis AT junrongzhu thediagnosticandprognosticvalueofthemir1792clusterinhepatocellularcarcinomaametaanalysis AT junrongzhu thediagnosticandprognosticvalueofthemir1792clusterinhepatocellularcarcinomaametaanalysis AT fanglu diagnosticandprognosticvalueofthemir1792clusterinhepatocellularcarcinomaametaanalysis AT fanglu diagnosticandprognosticvalueofthemir1792clusterinhepatocellularcarcinomaametaanalysis AT xianghongzhao diagnosticandprognosticvalueofthemir1792clusterinhepatocellularcarcinomaametaanalysis AT xianghongzhao diagnosticandprognosticvalueofthemir1792clusterinhepatocellularcarcinomaametaanalysis AT zhongqiuzhang diagnosticandprognosticvalueofthemir1792clusterinhepatocellularcarcinomaametaanalysis AT zhongqiuzhang diagnosticandprognosticvalueofthemir1792clusterinhepatocellularcarcinomaametaanalysis AT mengqiuxiong diagnosticandprognosticvalueofthemir1792clusterinhepatocellularcarcinomaametaanalysis AT yingwang diagnosticandprognosticvalueofthemir1792clusterinhepatocellularcarcinomaametaanalysis AT yingwang diagnosticandprognosticvalueofthemir1792clusterinhepatocellularcarcinomaametaanalysis AT yalansun diagnosticandprognosticvalueofthemir1792clusterinhepatocellularcarcinomaametaanalysis AT yalansun diagnosticandprognosticvalueofthemir1792clusterinhepatocellularcarcinomaametaanalysis AT bangshunhe diagnosticandprognosticvalueofthemir1792clusterinhepatocellularcarcinomaametaanalysis AT bangshunhe diagnosticandprognosticvalueofthemir1792clusterinhepatocellularcarcinomaametaanalysis AT junrongzhu diagnosticandprognosticvalueofthemir1792clusterinhepatocellularcarcinomaametaanalysis AT junrongzhu diagnosticandprognosticvalueofthemir1792clusterinhepatocellularcarcinomaametaanalysis |